incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 47,479.43 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...

The Maine CDC is excited to announce that we are modernizing our Tuberculosis (TB) reporting system. Currently, inactive TB (also known as Latent TB Infection or LTBI) cases and suspect and confirmed ...

GSK is funding public health organizations working to address US adult immunization gaps and increase community vaccine education, outreach and access These grants are part of GSK’s COiMMUNITY ...

He is accusing GSK, formerly known as GlaxoSmithKline, of hiding the cancer risks of its once-popular heartburn drug, Zantac. Yost filed a motion on Monday requesting that the Ohio Public ...

ET NOW Panellist Kunal Bothra has recommended three stocks – Asian Paints, GlaxoSmithKline Pharmaceuticals, and Indus Towers Ltd. Asian Paints Share Price Target 2025: Rs 2500; Stop Loss – Rs ...

The UK’s two biggest drug makers, AstraZeneca and GlaxoSmithKline, have some manufacturing bases in the US, which could help them dodge the levies to some extent. UK-based GlaxoSmithKline ...

MSD Pharmaceuticals' Gardasil 4 vaccine and Serum Institute's Cervavac are quadrivalent vaccines that target four HPV sub-types -- 6, 11, 16 and 18. MSD's Gardasil 9, which is India's first gender ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Upendra Singh, Commercial Head - General Medicines, effective from the close of business hours of 18th April 2025.

Big pharmaceutical companies have been making deals for technologies that could help them get their molecules through this protective membrane and now GSK is joining in, striking up an alliance ...

ABL Bio与葛兰素史克（GSK）签署了一项多项目协议，意在开发针对神经退行性疾病的新药。该协议将利用ABL Bio的Grabody-B平台技术，有效输送分子穿越血脑屏障。ABL Bio将获得高达7700万英镑的前期和近期支付，包括3850万英镑的立即支付及研究里程碑费用。总体而言 ...

SEONGNAM, South Korea I April 7, 2025 I ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...